Pipeline

Pipeline

Neumentum’s pipeline aims to address shortfalls of current pain management treatments by developing and commercializing effective and safe, non-opioid options without the risks of abuse, misuse and diversion seen with opioids, nor the opioid-induced side effects, including potentially life-threatening respiratory depression.
Product Timeline

Click image to expand

Neumentum’s pipeline aims to address shortfalls of current pain management treatments by developing and commercializing effective and safe, non-opioid options without the risks of abuse, misuse and diversion seen with opioids, nor the opioid-induced side effects, including potentially life-threatening respiratory depression.

NTM-006

A new chemical entity with a novel mechanism of action (MoA). In development for chronic neuropathic or nociplastic pain with the potential to offer significant benefits as a monotherapy or as part of a multimodal regimen.

NTM-001

Designed to deliver 24 hours of opioid level analgesia, reduce the potential analgesic gaps associated with bolus ketorolac, reduce or eliminate the need for postoperative opioids, and shorten the length of hospital stay.

Early Stage Pipeline

Including a novel intrathecal preparation of ketorolac and two novel non-opioid analgesic compounds with a similar MOA to acetaminophen (APAP), but with the potential to be more potent and without the liver toxicity associated with APAP.

Disclaimer: These are investigational new drug candidates and are not approved for any indication in any market